About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
|
|
|
201-500 employees
View all Madrigal Pharmaceuticals employees
|
|
Pharmaceuticals
|
|
$10M–$50M
|
|
(484) 567-2000
|
|
200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
|
|
2016
|
|
Liver Disease, Nash, Metabolic Disease
|
Madrigal Pharmaceuticals Alternatives
Frequently Asked Questions about Madrigal Pharmaceuticals
Paul Friedman is the CEO of Madrigal Pharmaceuticals. To contact Paul Friedman email at [email protected].
The decision makers in Madrigal Pharmaceuticals are Bill Sibold, Bob Orourke, Chris Dadas, etc. Click to Find Madrigal Pharmaceuticals decision makers emails.
Madrigal Pharmaceuticals headquarters is located at 200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US.
Madrigal Pharmaceuticals generates an estimated $10M–$50M annually, based on industry analysis and publicly available market data.
You can contact Madrigal Pharmaceuticals by calling (484) 567-2000.
Madrigal Pharmaceuticals Staff Directory
Search Madrigal Pharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
